The major protein that precipitates in the amyloid deposits in brains of humans and other mammals in aging, in Alzheimer's disease (AD) and Down's syndrome is a 39-43 amino acid protein termed AB. AB results from the proteolytic degradation of a larger precursor, the amyloid precursor protein (APP), and mutations in the APP in the region of AB are associated with familial AD. A second protein invariably associated with AB in amyloid deposits is the serine protease inhibitor alpha 1-antichymotrypsin (ACT). The precipitation of AB may result from the disturbance of the delicate balance between proteases and their inhibitors in brain, and agents that can modulate the proteolytic/inhibitory activities become candidates for therapeutic interventions aimed at lowering the levels of AB. For the past years, the investigators have studied the proteases involved in cleaving APP at or near the N-terminus of AB, and the role of ACT in this process. Their long-term objectives are to purify, clone and characterize the proteases identified in the first two years of this grant, and to prove their relevance to APP degradation. There are four specific aims:
The first aim i s to complete characterization and cloning of the calcium-activated serine protease (CASP) and compare its levels as a function of age and in AD and age-matched controls. CASP cleaves between lysine and methionine in a synthetic peptide flanking the N-terminus of AB, and can generate amyloidogenic fragments from APP; APP metabolism will be compared in CASP anti sense-transfected and untransfected cells.
The second aim i s to analyze the novel serine protease cloned from a human brain expression library. The cDNA probe will be used to determine its tissue-specific distribution. Antibodies have been generated against two peptides derived from the cDNA sequence which now will be used in the purification of the protease from tissues and cultured cells. Once purified, the protease activity will be tested against APP. They will also use anti sense RNA to knock-out its activity in primary cells and cell lines and follow the APP degradation in those cells.
The third aim i s to prove the relevance of a zinc metalloprotease, purified and sequenced by the investigators to APP processing. They will clone the cDNA of this protease and then also use anti sense probes to inactivate it in cultured cells.
The fourth aim i s to continue studies on ACT-like and cathepsin G-like proteins in primary mouse astrocytes and in human glioblastoma cell lines. In summary, the applicants propose to complete the characterization of three serine proteases and one metalloprotease and to prove their relevance to APP degradation and AD development.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG009905-06
Application #
2001375
Study Section
Neurological Sciences Subcommittee 1 (NLS)
Program Officer
Heemskerk, Jill E
Project Start
1991-05-01
Project End
1999-11-30
Budget Start
1996-12-01
Budget End
1999-11-30
Support Year
6
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Boston University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Sloane, J A; Hinman, J D; Lubonia, M et al. (2003) Age-dependent myelin degeneration and proteolysis of oligodendrocyte proteins is associated with the activation of calpain-1 in the rhesus monkey. J Neurochem 84:157-68
Mucke, L; Yu, G Q; McConlogue, L et al. (2000) Astroglial expression of human alpha(1)-antichymotrypsin enhances alzheimer-like pathology in amyloid protein precursor transgenic mice. Am J Pathol 157:2003-10
Abraham, C R; McGraw, W T; Slot, F et al. (2000) Alpha 1-antichymotrypsin inhibits A beta degradation in vitro and in vivo. Ann N Y Acad Sci 920:245-8
Sloane, J A; Hollander, W; Moss, M B et al. (1999) Increased microglial activation and protein nitration in white matter of the aging monkey. Neurobiol Aging 20:395-405
Abraham, C R; Marshall, D C; Tibbles, H E et al. (1999) Platelets and DAMI megakaryocytes possess beta-secretase-like activity. J Lab Clin Med 133:507-15
Yamin, R; Malgeri, E G; Sloane, J A et al. (1999) Metalloendopeptidase EC 3.4.24.15 is necessary for Alzheimer's amyloid-beta peptide degradation. J Biol Chem 274:18777-84
Simons, E R; Marshall, D C; Long, H J et al. (1998) Blood brain barrier endothelial cells express candidate amyloid precursor protein-cleaving secretases. Amyloid 5:153-62
Meckelein, B; Marshall, D C; Conn, K J et al. (1998) Identification of a novel serine protease-like molecule in human brain. Brain Res Mol Brain Res 55:181-97
Liang, J S; Fine, R E; Abraham, C R et al. (1996) The fibril forming region of the beta-amyloid precursor differs from that of the amyloid A precursor in its interaction with lipids. Biochem Biophys Res Commun 219:962-7
Meckelein, B; de Silva, H A; Roses, A D et al. (1996) Human endopeptidase (THOP1) is localized on chromosome 19 within the linkage region for the late-onset alzheimer disease AD2 locus. Genomics 31:246-9

Showing the most recent 10 out of 19 publications